Comparability of the tandem-R andIMx assays for the measurement of serum prostate-specific antigen
dc.contributor.author | Jacobsen, Steven J. | en_US |
dc.contributor.author | Lilja, Hans | en_US |
dc.contributor.author | Klee, George G. | en_US |
dc.contributor.author | Wright, Jr, George L. | en_US |
dc.contributor.author | Pettersson, Kim | en_US |
dc.contributor.author | Oesterling, Joseph E. | en_US |
dc.date.accessioned | 2006-04-10T17:52:22Z | |
dc.date.available | 2006-04-10T17:52:22Z | |
dc.date.issued | 1994-10 | en_US |
dc.identifier.citation | Jacobsen, Steven J., Lilja, Hans, Klee, George G., Wright, Jr, George L., Pettersson, Kim, Oesterling, Joseph E. (1994/10)."Comparability of the tandem-R andIMx assays for the measurement of serum prostate-specific antigen." Urology 44(4): 512-518. <http://hdl.handle.net/2027.42/31299> | en_US |
dc.identifier.uri | http://www.sciencedirect.com/science/article/B6VJW-4F5TTXG-36/2/dcacb2a80106db1b9a5e479013e0a0e2 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/31299 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=7524236&dopt=citation | en_US |
dc.description.abstract | Objectives.To assess the comparability of the Tandem-R and IMx serumprostate-specific antigen (PSA) assays across levels of the ratio of free-to-total serum PSA found in a community-based population of healthy men.Methods.Banked serum samples from the baseline component of the Olmsted CountyStudy of Urinary Symptoms and Health Status Among Men were thawed and analyzed using the Tandem-R and IMx PSA assays. Serum levels also were determined for the free, noncomplexed form of PSA, PSA complexed to alpha-1 antichymotrypsin, and total PSA with a research-based immunofluorometric assay.Results.The results of the Tandem-R and IMx assays were strongly correlated at alllevels of the ratio of free-to-total serum PSA. The Spearman correlation coefficients ranged from 0.87 to 0.98 (all p Conclusions.For the majority of men, results of the Tandem-R and IMx PSA assays were virtually identical. The small differences found would not be of clinical significance for most men but should be considered when comparing results of different assays in sequential determinations for a specific man. | en_US |
dc.format.extent | 1123809 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Elsevier | en_US |
dc.title | Comparability of the tandem-R andIMx assays for the measurement of serum prostate-specific antigen | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Health Sciences Research, Section of Clinical Epidemiology and Department of Laboratory Medicine and Pathology, Division of Metabolic and Hematologic Biochemistry, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA; Department of Clinical Chemistry, University of Lund, Mälmo, Sweden; Department of Microbiology and Immunology and Center for Urological Oncology,Eastern Virginia Medical School, Norfolk, Virginia, USA; Department of Biotechnology, University of Turku, Finland; The Michigan Prostate Institute, University of Michigan, Ann Arbor, Michigan, USA. | en_US |
dc.contributor.affiliationum | Department of Health Sciences Research, Section of Clinical Epidemiology and Department of Laboratory Medicine and Pathology, Division of Metabolic and Hematologic Biochemistry, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA; Department of Clinical Chemistry, University of Lund, Mälmo, Sweden; Department of Microbiology and Immunology and Center for Urological Oncology,Eastern Virginia Medical School, Norfolk, Virginia, USA; Department of Biotechnology, University of Turku, Finland; The Michigan Prostate Institute, University of Michigan, Ann Arbor, Michigan, USA. | en_US |
dc.contributor.affiliationum | Department of Health Sciences Research, Section of Clinical Epidemiology and Department of Laboratory Medicine and Pathology, Division of Metabolic and Hematologic Biochemistry, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA; Department of Clinical Chemistry, University of Lund, Mälmo, Sweden; Department of Microbiology and Immunology and Center for Urological Oncology,Eastern Virginia Medical School, Norfolk, Virginia, USA; Department of Biotechnology, University of Turku, Finland; The Michigan Prostate Institute, University of Michigan, Ann Arbor, Michigan, USA. | en_US |
dc.contributor.affiliationum | Department of Health Sciences Research, Section of Clinical Epidemiology and Department of Laboratory Medicine and Pathology, Division of Metabolic and Hematologic Biochemistry, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA; Department of Clinical Chemistry, University of Lund, Mälmo, Sweden; Department of Microbiology and Immunology and Center for Urological Oncology,Eastern Virginia Medical School, Norfolk, Virginia, USA; Department of Biotechnology, University of Turku, Finland; The Michigan Prostate Institute, University of Michigan, Ann Arbor, Michigan, USA. | en_US |
dc.contributor.affiliationum | Department of Health Sciences Research, Section of Clinical Epidemiology and Department of Laboratory Medicine and Pathology, Division of Metabolic and Hematologic Biochemistry, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA; Department of Clinical Chemistry, University of Lund, Mälmo, Sweden; Department of Microbiology and Immunology and Center for Urological Oncology,Eastern Virginia Medical School, Norfolk, Virginia, USA; Department of Biotechnology, University of Turku, Finland; The Michigan Prostate Institute, University of Michigan, Ann Arbor, Michigan, USA. | en_US |
dc.contributor.affiliationum | Department of Health Sciences Research, Section of Clinical Epidemiology and Department of Laboratory Medicine and Pathology, Division of Metabolic and Hematologic Biochemistry, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA; Department of Clinical Chemistry, University of Lund, Mälmo, Sweden; Department of Microbiology and Immunology and Center for Urological Oncology,Eastern Virginia Medical School, Norfolk, Virginia, USA; Department of Biotechnology, University of Turku, Finland; The Michigan Prostate Institute, University of Michigan, Ann Arbor, Michigan, USA. | en_US |
dc.identifier.pmid | 7524236 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/31299/1/0000205.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1016/S0090-4295(94)80049-9 | en_US |
dc.identifier.source | Urology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe its collections in a way that respects the people and communities who create, use, and are represented in them. We encourage you to Contact Us anonymously if you encounter harmful or problematic language in catalog records or finding aids. More information about our policies and practices is available at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.